Martin Brenner

Directeur Général chez IBIO, INC.

Fortune : 58 239 $ au 31/05/2026

56 ans

Health Technology

Consumer Services

Profil

Martin B. Brenner currently works at iBio, Inc., as Director, Chief Executive & Scientific Officer from 2024.
Dr. Brenner also formerly worked at AstraZeneca PLC, as Senior Director & Head-BioScience from 2012 to 2013, Merck Research Laboratories Massachusetts LLC, as Executive Director-Diabetes & NASH from 2013 to 2016, Recursion Pharmaceuticals, Inc., as Chief Scientific Officer from 2017 to 2018, Pelican, Inc., as Chief Scientific Officer & Senior Vice President from 2019 to 2020, Stoke Therapeutics, Inc., as VP & Head-Research & Early Development from 2016 to 2017, and Pfizer Inc., as Head-Insulin Resistance Group.
Dr. Brenner received his doctorate degree from Ludwig-Maximilians-Universität München and doctorate degree from The University of Veterinary Medicine Hanover.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
IBIO, INC. 0,09%	19/03/2026	30 652 ( 0,09% )	58 239 $	31/05/2026

Postes actifs de Martin Brenner

Sociétés	Poste	Début
IBIO, INC.	Directeur Général	20/01/2023

Tous les postes actifs de Martin Brenner

Anciens postes connus de Martin Brenner

Sociétés	Poste	Fin
PFENEX INC.	Directeur Technique/Scientifique/R&D	01/10/2020
RECURSION PHARMACEUTICALS, INC.	Directeur Technique/Scientifique/R&D	01/01/2018
STOKE THERAPEUTICS, INC.	Corporate Officer/Principal	01/01/2017
Merck Research Laboratories Massachusetts LLC Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products	Directeur/Membre du Conseil	01/01/2016
ASTRAZENECA PLC	Corporate Officer/Principal	01/01/2013

Voir l'expérience en détail de Martin Brenner

Formation de Martin Brenner

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Martin Brenner

Relations

Relations au 1er degré

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Entreprise privées	9
Pfizer Inc. Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients	Health Technology
AstraZeneca PLC AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products	Health Technology
Recursion Pharmaceuticals, Inc. Recursion Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that combines biology, chemistry, automation, data science and engineering to industrialize drug discovery	Health Technology
Ludwig-Maximilians-Universität München Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Merck Research Laboratories Massachusetts LLC Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products	Health Technology
iBio, Inc. iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins	Health Technology
Pelican Inc Pelican Inc Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical therapeutics and vaccines	Health Technology
The University of Veterinary Medicine Hanover The University of Veterinary Medicine Hanover Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Stoke Therapeutics, Inc. Stoke Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company focused on the development of first-in-class therapeutics that selectively increase gene expression to treat genetic diseases	Health Technology